Alnylam has both acquired Merck & Co. subsidiary Sirna therapeutics and extended an alliance with Genzyme in order to advance its small interfering RNA (siRNA) delivery programme.
Chinese API firm Shenzhen Hepalink has announced plans to buy Scientific Protein Laboratories (SPL) from private equity investor American Capital for $337.5m.
Encap has collaborated with Lipocine to manufacture its oral testosterone product and says it expects continued growth in demand for HPAPI formulation services.
Pfizer says it intends to shutter a manufacturing facility in Puerto Rico just days after Merck & Co. announced it was reducing its footprint on the island.
Granules India has outlined plans to buy drug intermediate and API maker Auctus Pharma, set up an actives R&D site and announced its intention to wind up its ‘shell’ operation in Singapore.
The acquisition of Bend Research by Capsugel may be “a marriage made in heaven” for customers, the firms say, as the first drug delivery tech is transferred.
GlaxoSmithKline is in talks with a number of companies interested in buying its Romanian manufacturing facility that was recently earmarked for closure.
Amgen spent $10.4bn (€7.8bn) this week on Onyx Pharmaceuticals, but AstraZeneca and Johnson & Johnson have also opened up their wallets this week – welcome to in-Pharmatechnologist.com’s merger & acquisition round-up.
Amgen has spent $10.4bn (€7.8bn) in acquiring Onyx Pharmaceuticals saying its oncology products and pipeline will be strengthened by Amgen’s manufacturing capabilities.
Consolidating its Indian injectable business under a new subsidiary will improve focus and align quality control, says Aurobindo who has invested in two manufacturing companies to support such plans.
Enteris has acquired an oral drug delivery platform from Unigene Laboratories and says the excipients used can increase solubility and absorption for both peptides and small molecules.
Bristol-Myers Squibb says shuttering Amylin’s San Diego facilities will accelerate its diabetes R&D joint venture with AstraZeneca though approximately 300 jobs will be lost.
As the dissolution of Angel continues, its core manufacturing facility has been bought by AB Technology ensuring long term operations and rescuing 23 jobs.
Following last week’s shuttering of a manufacturing plant administrators have sold Angel Biomedical to new company Collbio as they start offloading CMOs assets.
Patheon says the shuttering of one of Banner’s manufacturing sites is necessary in integrating the recent acquisition into its global business structure.
Teva says the offloading of its Californian manufacturing facility is part of cost-cutting plans designed to save $2bn (€1.5bn). in the next few years.
German chemicals giant BASF expects its revised takeover bid for Norwegian omega-3 API manufacturer Pronova Biopharma ASA to be accepted by resistant shareholders.
BASF says revised offer for omega-3 API maker Pronova Biopharma is fair value given recent Greek Government decision to stop reimbursing two key drugs.
German fragrance and flavours house Symrise has just last night inked a deal with Swedish probiotics firm Probi to develop a stand-alone R&D project with oral probiotic supplements the most likely product out of the pipeline in 2014-2015.
BASF on Friday invited the Scottish First Minister, Alex Salmond, to officially open its newly acquired and now expanded high concentration omega-3 facility on the Isle of Lewis in the Hebrides, west Scotland.
BASF’s ever-expanding nutrition unit says its €644m bid last week bid for Norwegian omega-3 firm, Pronova Biopharma, is as important for its food supplements business as its pharmaceutical operations.